A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...

British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...

GSK has reported promising results with a drug to treat the severe itching that plagues patients with rare cholestatic liver ...

Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented ...

Tharimmune (THAR) presented new TH104 clinical data at the American Association for the Study of Liver Disease The Liver Meeting 2024, underway in San Diego from November 15-19. The Phase 1 trial was ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024PARIS, FRANCE, 18 ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...

Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...

The Air Quality Index (AQI) remains severe to hazardous in Delhi NCR which is a leading cause of the rise in respiratory and ...

Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the ...

The sNDA was submitted to support full approval of OCA for this indication based on data from the COBALT trial, as well as real-world evidence.